Preventing filamin A/AR complex assembly in pCAFs using a stapled peptide resulted in reduction in size of three-dimensional LNCaP/pCAF cell spheroids hence targeting this axis with highly specific peptide-disruptors may serve to treat prostate tumour growth and metastasis or alternatively as a novel biomarker [101]. The gene discussed is FLNA; the disease is prostate neoplasm.